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Abstract
Background and purpose: Duchenne/Becker muscular dys-
trophies (DMD/BMD) lead to progressive irreversible mus-
cle deterioration caused by recessive mutations in the dys-
trophin encoding gene (Xp21.1). Approximately 60% of
mutations are deletions, 10% are duplications and the remain-
ing 30% are point mutations. The aim of the study is to pre-
sent the rare occurrence of two pathogenic mutations (dele-
tions or duplications) in one allele of the dystrophin gene.
Material and methods: DNA of patients from 1364 DMD/
BMD families was tested. Two techniques – PCR-multiplex
and multiplex ligation-dependent probe amplification – were
used to search for mutations in the dystrophin gene.
Results: Deletion was detected in 648 families and duplica-
tion was found in 74 families (analysis in progress). In two
families, presence of two mutations in one gene was docu-
mented – in the first family two deletions were found (exons
45-49 and 60-61), and in the second family two duplications
were detected (exons 2-7 and 50-59). One of the deletions
disrupted the reading frame, and the other deletion retained
the reading frame. Both duplications also retained the read-
ing frame of the gene but in both families the disease took
a severe course (DMD). In the family with two duplications
prenatal diagnosis was also carried out, and carriership of
both mutations was discovered in the female fetus.
Conclusions: In the analyzed group of DMD/BMD fami-
lies, the frequency of combined occurrence of two mutations
in one gene was 2 per 722 (0.3%). The phenomenon of de -
tected non-contiguous deletions and duplications is present-
ed together with 31 similar cases published so far.
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St reszc zen ie
Wstêp i cel pracy: Dystrofia miêœniowa Duchenne’a/Beckera
(DMD/BMD) jest zwi¹zana z postêpuj¹cym i nieodwracal-
nym zanikiem miêœni wywo³anym recesywnymi mutacjami
w genie dystrofiny (Xp21.1). Szacuje siê, ¿e 60% mutacji sta-
nowi¹ delecje, a 10% – duplikacje; pozosta³e 30% mutacji ma
charakter punktowy. Celem pracy jest przedstawienie rzad-
kich przypadków wspó³wyst¹pienia w jednym allelu genu dys-
trofiny dwóch chorobotwórczych mutacji – delecji lub dupli-
kacji.
Materia³ i metody: Badano DNA pacjentów z 1364 rodzin
skierowanych z podejrzeniem DMD lub BMD. Mutacji
poszukiwano, u¿ywaj¹c dwóch technik: PCR-multiplex
i MLPA (multiplex ligation-dependent probe amplification). 
Wyniki: W 648 rodzinach wykryto delecjê, a w 74 rodzinach
– duplikacjê (badania w toku). W dwóch rodzinach udoku-
mentowano ³¹czne wyst¹pienie w jednym genie dystrofiny
dwóch mutacji – w pierwszej rodzinie w jednym allelu wykry-
to dwie delecje (eksony 45-49 i 60-61), a w drugiej rodzinie
dwie duplikacje (eksony 2-7 i 50-59). Jedna z delecji naru-
sza³a fazê odczytu, druga zaœ j¹ zachowywa³a; obie duplika-
cje zachowywa³y fazê odczytu, jednak w obu rodzinach cho-
roba przybiera³a ostr¹ postaæ (DMD). W rodzinie, w której
wykryto dwie duplikacje, wykonano diagnostykê prenataln¹,
stwierdzaj¹c u p³odu p³ci ¿eñskiej nosicielstwo obu mutacji.
Wnioski: W analizowanej grupie rodzin z delecj¹ lub dupli-
kacj¹ czêstoœæ ³¹cznego wyst¹pienia dwóch mutacji wynios³a
2 na 722 (0,3%). Zjawisko wykrytych nieci¹g³ych delecji
i duplikacji przedstawiamy w zestawieniu z opisanymi dotych-
czas 31 podobnymi przypadkami.
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Introduction
Duchenne muscular dystrophy (DMD) (MIM
310200) and Becker muscular dystrophy (BMD)
(MIM 300376) are caused by mutations in the dys-
trophin gene localized at Xp21. Incidence of DMD 
is estimated to be 1 : 3500 of living male births, while
the incidence of less severe BMD is five times lower [1].
The dystrophin gene, the largest human gene, consists
of 79 exons. Mutations causing DMD/BMD include
deletions (60%), duplications (10%), and point muta-
tions (30%). Deletions can involve a various extent of
the gene, from one exon to all exons. Duplications are
of similar size. Point mutations are alterations of one,
several or a dozen nucleotides within exons or at the
intron-exon border [2].
According to Monaco et al. [3], mutations leading
to a stop codon, either due to the substitution of one
nucleotide with another, or due to a frame shift, result
in complete lack of dystrophin and produce the severe
disease form, i.e. DMD. Mutations that do not inter-
fere with the reading frame (deletions or duplications
that are multiplications of complete trinucleotide codons)
lead to the synthesis of a truncated protein that might
partially fulfill its role within the muscle fiber, resulting
in a milder form of the disease, i.e. BMD. The theory
of frame shift or its preservation is appropriate in 90%
of cases. In another 10%, deletions may not include 
the whole exons or may affect the mRNA splicing in
such a way that mRNA does not exactly match other
exons within the gene. It is also theoretically possible
that the deletion with the preserved reading frame coex-
ists with the point mutation leading to the stop codon.
The compliance of duplications with Monaco's theory
is lower and may reach only 70% [4].
We present the coexistence of two different mutations
in one allele of the dystrophin gene leading to DMD/
BMD. This phenomenon is very rare and in Poland it
was documented for the first time in our labo ratory.
Material and methods
Between 1991 and 2011, the Department of Gene -
tics (Institute of Psychiatry and Neurology) collected
DNA samples of members of 1364 families, referred
with suspected DMD/BMD. Mutations were sought
initially with hybridization and PCR-multiplex, and
since 2009 with the method of multiplex ligation-depen-
dent probe amplification (MLPA). PCR-multiplex
used the set of primer pairs for the following exons: 
1, 2, 3, 4, 6, 7, 8, 11, 12, 13, 17, 19, 20-22, 29, 34, 
42-55, 60 (www.dmd.nl/DMD_mPCR.html), while
the MLPA method used two sets of reagents allowing
for the qualitative and quantitative assessment of all 
79 exons of the dystrophin gene: SALSA P034 and
SALSA P035 (MRC-Holland, Amsterdam, The Ne -
therlands).
Patients
The mutations presented below were detected in
DNA of subjects from two families: D166 – three boys
affected with DMD were tested; women, obligatory car-
riers, were not tested with molecular methods (Fig. 1A);
and D1299 – four healthy women suspected of being
mutation carriers were tested and additionally prenatal
testing was performed (trophoblast sampled at 12 weeks
of pregnancy); a DNA sample was not available in the
case of a deceased male member of the family in whom
DMD was diagnosed clinically (Fig. 1B).
Results
Among studied DNA samples, deletions in the dys-
trophin gene were detected in 648 families, and dupli-
cations in 74 families. Among those 722 families there
were two families with coexistence of two mutations in
one allele in affected men and in female carriers. Those
families (pedigrees D166 and D1299) are described
below (Figs. 1A-B).
In D166 pedigree (Fig. 1A), two deletions in exons
45-49 and 60-61 (c.[6439-?_7200+?del; 8938-?_9163
+?del]) were detected in the dystrophin gene of the
proband (IV-2) (the extent of deletions in the adjacent
introns in unknown). Figure 2A shows the result of
MLPA testing (control testing – Fig. 2C). The first
deletion did not disrupt the reading frame, while the
second one shifted the frame by one nucleotide, lead-
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ing to the change of 33 amino acids coded by exon 62
and part of exon 63; it also resulted in a stop codon in
exon 63 (proband IV-2). The same two deletions were
detected in the two other affected boys (III-7 and III-8).
All three patients were affected with the acute form of
the disease (DMD). The mothers of the affected boys
(II-4 and III-6), who were obligatory carriers, were not
tested with molecular methods.
In D1299 pedigree (Fig. 1B), two duplications af -
fecting exons 2-7 and 50-59 (c.[ 32-?_649+?dup; 7201-
?_8937+?dup]) were detected in the dystrophin gene
of the tested female subject (II-9) who was the sister of
a boy who died 20 years ago because of DMD (the
extent of duplications in the adjacent introns is un -
known). Figure 2B shows the result of MLPA testing
(control testing – Fig. 2C). Those duplications did not
disrupt the open reading frame. The same duplications
were found in the mother (I-2), sister (II-6) and daugh-
ter (III-3) of the female patient. Patient III-3 decided
to be tested prenatally because of the risk of giving birth
Fig. 1. A) Pedigree of the D166 family. Affected boys are marked in black, the proband is indicated by an arrow. The following male members of the family were ana-
lyzed: III-7, III-8 and IV-2 
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Fig. 1. B) Pedigree of the D1299 family. The affected boy is marked in black; the proband is indicated by an arrow. The following members of the family were ana-
lyzed: I-2, II-6, II-9, III-3 and IV-1 (prenatal test). DNA of the proband was not available
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Fig. 2. Results of DNA analysis carried out by MLPA method: (A) DMD patients from D166 family (III-7) – deleted exons: 45-49 and 60-61; missing peaks due to
deletion marked by arrows; (B) prenatal diagnosis in D1299 family – female fetus (IV-1), a carrier of duplicated exons: 2-7 and 50-59; elevated peaks due to dupli-
cation are marked by arrows; (C) control DNA – unaffected male
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to a child affected with DMD. DNA testing in the fe -
male fetus (IV-1) found the same duplications. 
Discussion
The occurrence of two mutations in one dystrophin
gene is a rare finding; it was demonstrated for the first
time by Hoopa et al. [5], who found the co-occurrence
of two deletions involving exons 12-17 and 50-51. One
year later, Florenti et al. [6] found two deletions (19-
21 and 26-29) in one gene. Numerous studies per-
formed in the 1990s, involving the search for deletions
in pa tients with DMD/BMD using either PCR-mul-
tiplex or very laborious hybridization, did not reveal any
further cases of double mutations. It was the introduc-
tion of MLPA technique that enabled fast and simul-
taneous testing of presence and quantity of all 79 exons
and resulted in reports on two mutations in one allele of
the dystrophin gene.
In 2004, the coexistence of deletions in exons 1 and
3-11 was reported [7, www.dmd.nl] but subsequently it
was corrected – finally, the duplication of exon 1 and
exons 3-9 was established. One year later, the co-occur-
rence of two duplications of exons 45-48 and 54-55 was
reported [8]. In the following year, White et al. [9]
described four cases of complex duplications, including
two with the fragments in a triple dose (i.e. triplication).
Then, several papers on other duplications, termed by
the authors non-contiguous duplications, were published
[10-15].
The results of two large studies showed that the pre -
sence of more than two mutations in one gene, although
extremely rare, is also possible [16,17]. The largest
database of complex deletions and duplications can be
found at www.dmd.nl, although not all cases are includ-
ed. Table 1 provides a list of 33 cases of double dele-
tions and duplications, including two families reported
here.
The data compilation presented in Table 1 and Fig-
ure 3 suggests that double duplications are the most
prevalent complex mutations; double deletions are infre-
quent and coexistence of duplication with deletion is
even more rare, similarly to cases with duplications asso-
ciated with tri- or quadruplications.
The case of two deletions detected by us results 
in the acute form of the disease. The first deletion (exons
45-49) does not disrupt the reading frame and could
result in a relatively mild course of the disease, but the
other deletion (exons 60-61), disrupting the reading
frame and leading to the stop codon in exon 63, leads
Mutations Reference and year
detected of publication
P-2 del; 44 del ESHG* 2004
P dupl; 2 dupl [17] 2009
P-1 dupl; 2-7 dupl [14] 2008
P-1 dupl; 3-9 dupl [7] 2004
P-1 dupl; 45-55 dupl www.dmd.nl**
1-8 dupl; 45-52 del [12] 2008
2-7 dupl; 50-55 dupl [15] 2008
3-12 dupl; 38-47 dupl www.dmd.nl**
5-7 del; 10-11 del [17] 2009
5-13 dupl; 45-52 dupl [10] 2007
5-18 dupl; 19-41 tripl; 42 dupl; [9] 2006
43-44 tripl
5-19 dupl; 38-41 dupl [9] 2006
9-16 dupl; 31-32 dupl; 38-42 dupl [12] 2008
10-16 dupl; 22-44 dupl [16] 2009
13-19 del; 31-45 quadr; 46-48 dupl; [12] 2008
51-52 dupl
19-21 del; 26-29 del [6] 1995
29 dupl; 45 dupl [16] 2009
29-33 dupl; 34-36 tripl; 37-51 dupl [12] 2008
30-35 dupl; 48-50 del [12] 2008
43-44 dupl; 45-47 del ESHG 2004
43-45 dupl; 56-74 dupl www.dmd.nl**
43-47 dupl; 60-67 dupl [4] 2008
43-51 dupl; 53-60 dupl [14] 2008
44 dupl; 51-55 dupl [7] 2004
45-48 dupl; 51-55 dupl [12] 2008
45-48 dupl; 54-55 dupl [8] 2005
45-48 dupl; 55-63 dupl [13] 2008
45-55 dupl; 65-79 dupl [9] 2006
50-60 dupl; 63-79 dupl [16] 2009 
52-55 dupl; 63-67 dupl; 68-79 tripl [9] 2006
54-59 dupl; 63-79 dupl [17] 2009
45-49 del; 60-61 del Our own data
2-7 dupl; 50-59 dupl Our own data
Table 1. Reported non-contiguous deletions and duplications in the dystrophin
gene according to www.dmd.nl (Fig. 3 illustrates the schema of non-con-
tiguous mutations)
*Data presented at the meeting of the European Society of Human Genetics
**Website of Leiden University Medical Center, the Netherlands
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to the marked shortening of the protein, deprives it of
two very important domains (cysteine-rich and C-ter-
minal ones) and produces the acute form of the disease
(DMD).
Our second case, with two duplications in the dys-
trophin gene, is very similar to that reported by Spa nish
authors [15]. In both cases, duplication at the 5’-termi -
nal involves exons 2-7, and duplication in the hotspot of
the 3’-terminal involves exons 50-59 in our case and
exons 50-55 in the Spanish case. Despite the preserva-
tion of the reading frame in both those deletions, the
introduction of two important changes to the dystrophin
protein, especially the one related to the N-terminal
domain responsible for the binding of dystrophin with
the cytoskeleton of the muscle fiber, may result in the
same effect as the single mutation which disrupts the
reading frame. We are not aware, however, of the loca-
tion and orientation of the replication of the gene frag-
ment; also we do not know how it translates into the se -
quence present in the mRNA. The result of DNA
test ing only reports the summarized number of parti -
cular exons.
Families in whom the reported deletions and dupli-
cations were found, as in the case of other families affect-
ed with DMD/BMD, are managed by the out-patient
genetic clinic and have access to prenatal diagnosis. To
date, this opportunity has been used by one of the above-
mentioned carriers. The healthy daughter is a carrier of
Fig. 3. A schematic representation of the distribution of published noncontiguous mutations listed in Table 1
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the double duplication in the dystrophin gene, similarly
to her mother and grandmother.
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